Form 4: Vivani Medical's Chief Medical Officer Granted Stock Options and Restricted Stock Units

Lisa Porter, Chief Medical Officer of Vivani Medical, received stock options for 80,000 shares and 40,000 restricted stock units (RSUs) on May 10, 2024, as disclosed in a recent SEC filing.

Summary

• Lisa Porter, the Chief Medical Officer of Vivani Medical, Inc., was granted stock options and restricted stock units (RSUs).
• The stock options are for 80,000 shares with an exercise price of $1.81, vesting over 4 years, and expiring on May 9, 2034.
• The RSUs are for 40,000 shares and vest in three stages based on the company's stock price reaching $3.15 for three consecutive trading days, with subsequent vesting milestones one and two years after the initial price target is met.
• A Limited Power of Attorney was executed on December 6, 2023, granting Adam Mendelsohn, Judy Wong, and Brigid Makes the authority to execute SEC forms on behalf of Lisa Porter.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which are generally viewed positively as they align management interests with shareholder value. The performance-based vesting adds a further positive element.

Positives

• The grant of stock options and RSUs to the Chief Medical Officer aligns her interests with those of the shareholders.
• The performance-based vesting of the RSUs incentivizes the achievement of a specific stock price target.

Risks

• The RSUs will expire if the stock price does not reach $3.15 within four years from the grant date.
• The vesting of the stock options and RSUs is contingent on continued service, so there is a risk of forfeiture if the officer leaves the company.

Future Outlook

The vesting of the RSUs is contingent on future stock performance, specifically reaching and maintaining a price of $3.15 for three consecutive trading days.

Industry Context

Granting stock options and RSUs to key executives is a common practice in the biotechnology industry to incentivize performance and retain talent.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often vesting over a 3-4 year period.
• Performance-based RSUs are also common, with vesting tied to specific milestones such as clinical trial results, regulatory approvals, or stock price targets.
• Comparable companies like Amarin Corporation and Biohaven Pharmaceutical have used similar equity-based compensation strategies to align executive incentives with shareholder value.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to improve company performance and increase shareholder value.
• Employees may be motivated by the potential for future equity grants and the overall success of the company.

Key Dates